Diabetic Retinopathy
Current Pharmacologic Treatment and Emerging Strategies
Nonfiction, Health & Well Being, Medical, Specialties, Ophthalmology, Internal Medicine, Endocrinology & Metabolism
| Author: | Michael W. Stewart | ISBN: | 9789811035098 |
| Publisher: | Springer Singapore | Publication: | April 7, 2017 |
| Imprint: | Adis | Language: | English |
| Author: | Michael W. Stewart |
| ISBN: | 9789811035098 |
| Publisher: | Springer Singapore |
| Publication: | April 7, 2017 |
| Imprint: | Adis |
| Language: | English |
A well-illustrated and comprehensive analysis of the treatment of diabetic retinopathy, this book covers current treatment options and guidelines, whilst also providing a detailed discussion of emerging therapeutic targets.
Existing therapeutic options are covered in depth, with a major focus on anti-vascular endothelial growth factor drugs and sustained release corticosteroids, including a review of trial results supporting current treatment guidelines. The use of agents off-label is also discussed. Controversial topics are discussed in detail with an emphasis on helping the reader make informed decisions, particularly when treating patients for which several treatment approaches may be appropriate because trial data does not clearly define the best option.
Emerging therapeutic areas are evaluated, as work continues to identify agents that produce superior morphologic responses and visual acuity gains by targeting other molecules that contribute to diabetic retinopathy. Promising new drugs, targets and delivery systems are identified, and their development analysed.
A well-illustrated and comprehensive analysis of the treatment of diabetic retinopathy, this book covers current treatment options and guidelines, whilst also providing a detailed discussion of emerging therapeutic targets.
Existing therapeutic options are covered in depth, with a major focus on anti-vascular endothelial growth factor drugs and sustained release corticosteroids, including a review of trial results supporting current treatment guidelines. The use of agents off-label is also discussed. Controversial topics are discussed in detail with an emphasis on helping the reader make informed decisions, particularly when treating patients for which several treatment approaches may be appropriate because trial data does not clearly define the best option.
Emerging therapeutic areas are evaluated, as work continues to identify agents that produce superior morphologic responses and visual acuity gains by targeting other molecules that contribute to diabetic retinopathy. Promising new drugs, targets and delivery systems are identified, and their development analysed.
